Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Proc Natl Acad Sci U S A
2011 May 03;10818:7535-40. doi: 10.1073/pnas.1019559108.
Show Gene links
Show Anatomy links
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Katayama R
,
Khan TM
,
Benes C
,
Lifshits E
,
Ebi H
,
Rivera VM
,
Shakespeare WC
,
Iafrate AJ
,
Engelman JA
,
Shaw AT
.
???displayArticle.abstract???
The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a molecular target in a small subset of non-small cell lung cancers (NSCLCs). This fusion leads to constitutive ALK activation with potent transforming activity. In a pivotal phase 1 clinical trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions. However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clinical benefit. To determine how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-positive NSCLC cell line to increasing doses of crizotinib until resistance emerged. We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene. Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib. This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay. Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we observed that two structurally different ALK inhibitors, NVP-TAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo. Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG. Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.
Bean,
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
2007, Pubmed
Bean,
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
2007,
Pubmed
Chandarlapaty,
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
2010,
Pubmed
Chen,
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
2010,
Pubmed
Chiarle,
The anaplastic lymphoma kinase in the pathogenesis of cancer.
2008,
Pubmed
Choi,
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
2010,
Pubmed
,
Echinobase
Corcoran,
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
2010,
Pubmed
Engelman,
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
2008,
Pubmed
Engelman,
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
2007,
Pubmed
Engelman,
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
2006,
Pubmed
Engelman,
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
2008,
Pubmed
Faber,
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
2009,
Pubmed
Flaherty,
Inhibition of mutated, activated BRAF in metastatic melanoma.
2010,
Pubmed
Guix,
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
2008,
Pubmed
Johannessen,
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
2010,
Pubmed
Kantarjian,
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
2010,
Pubmed
Kobayashi,
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
2005,
Pubmed
Kosaka,
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
2006,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Kwak,
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
2005,
Pubmed
Mano,
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
2008,
Pubmed
,
Echinobase
McDermott,
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
2008,
Pubmed
Mok,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
2009,
Pubmed
O'Hare,
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
2005,
Pubmed
Pao,
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
2005,
Pubmed
Saglio,
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
2010,
Pubmed
Sasaki,
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
2010,
Pubmed
Sequist,
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
2010,
Pubmed
Shinmura,
EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
2008,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Soda,
A mouse model for EML4-ALK-positive lung cancer.
2008,
Pubmed
Takeuchi,
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.
2009,
Pubmed
Turke,
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
2010,
Pubmed
Yap,
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
2010,
Pubmed
Zheng,
Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.
2000,
Pubmed
Zhou,
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
2009,
Pubmed
